Dec 30, 2025 • MarketBeat
BULLISH
Ethic Inc. Acquires 11,638 Shares of AstraZeneca PLC $AZN
Ethic Inc. significantly increased its stake in AstraZeneca PLC by 16.0% in Q3, acquiring an additional 11,638 shares and bringing its total holdings to 84,382 shares valued at approximately $6.47 million. AstraZeneca reported strong Q3 earnings, surpassing analyst expectations with an EPS of $1.19 and revenue of $15.19 billion, while analyst sentiment remains largely positive with a "Moderate Buy" consensus. The stock trades near $92.52 with a market capitalization of $287 billion and a consensus target price of $95.75.
Dec 28, 2025 • MarketBeat
BULLISH
Valicenti Advisory Services Inc. Has $4.66 Million Holdings in AstraZeneca PLC $AZN
Valicenti Advisory Services Inc. (VASI) significantly reduced its stake in AstraZeneca PLC (NASDAQ:AZN) by 20.1% in the third quarter, now holding 60,696 shares valued at approximately $4.66 million. This position represents about 1.0% of VASI's investment portfolio. Despite other institutional investors increasing their holdings, AstraZeneca recently surpassed quarterly earnings and revenue estimates and maintains a "Moderate Buy" consensus rating from Wall Street analysts.
Dec 27, 2025 • MarketBeat
BULLISH
DAVENPORT & Co LLC Increases Stake in AstraZeneca PLC $AZN
DAVENPORT & Co LLC increased its stake in AstraZeneca PLC by 174.3% during the third quarter, adding 31,061 shares to hold 48,878 shares valued at approximately $3.75 million. This coincides with AstraZeneca reporting strong Q3 earnings, beating analyst estimates with an EPS of $1.19 and revenue of $15.19 billion, marking a 12% year-over-year increase. The company's stock currently trades near $92.90 with a "Moderate Buy" consensus rating from analysts, who set an average price target of $95.75.
Dec 25, 2025 • MarketBeat
BULLISH
Robbins Farley Purchases 27,582 Shares of AstraZeneca PLC $AZN
Robbins Farley significantly increased its holdings in AstraZeneca PLC (NASDAQ:AZN) by 103.8% in Q3, acquiring an additional 27,582 shares to hold a total of 54,149 shares valued at $4.154 million. This move positions AZN as the firm's 29th largest holding, comprising about 1.7% of its portfolio. Several other institutional investors also substantially boosted their stakes, contributing to hedge funds and institutional investors now owning approximately 20.35% of AstraZeneca stock.
Dec 24, 2025 • Bloomberg Law News
NEUTRAL
AstraZeneca Reaches Settlement With MSN Labs Over Cancer Drug
AstraZeneca Plc has settled a patent infringement dispute with MSN Laboratories Pvt Ltd. concerning its blood-cancer drug, Calquence. The settlement, formalized by a federal court in Delaware, enjoins MSN from infringing specific patents related to the drug's active ingredient, acalabrutinib maleate. The lawsuit alleged that MSN's tablets infringed two of AstraZeneca's patents for Calquence.
Dec 24, 2025 • MarketBeat
BULLISH
Swedbank AB Buys 286,904 Shares of AstraZeneca PLC $AZN
Swedbank AB increased its holdings in AstraZeneca PLC by 7.0% in the third quarter, purchasing an additional 286,904 shares to own a total of 4,364,458 shares, valued at approximately $334.84 million. AstraZeneca has shown strong financial performance, beating earnings estimates with $1.19 EPS and revenue of $15.19 billion, and analysts maintain a positive outlook with a "Moderate Buy" rating. The company's stock currently has a market capitalization of $285.77 billion and a price-to-earnings ratio of 30.61.